Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04280900
Other study ID # RBHP 2019 BROUSSE
Secondary ID 2019-A02368-49
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2020
Est. completion date December 31, 2021

Study information

Verified date February 2020
Source University Hospital, Clermont-Ferrand
Contact Lise Laclautre
Phone 334.73.754.963
Email promo_interne_drci@chu-clermontferrand.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cocaine addiction is a multifactorial disease with important consequences: somatic, psychiatric... The number of applications for treatment for cocaine addiction is gradually increasing from year to year but no conventional treatment is available. New tools such as virtual reality could be used in this treatment. We propose to create a virtual reality program based on the analysis of high-risk relapse situations described by patients. We will then assess the effect of this cybertherapy on patients' relapse time and their desire to use cocaine


Description:

In France, according to the Health Barometer 2017, cocaine testing has seen two decades of increases from 1.2% in 1995 to 5.6% in 2017, making it the second most widely used illicit substance. About 5% of cocaine users may become addicted in the first year of use, while 20% will develop long-term addiction. This dependence or substance use disorder is characterized in particular by a loss of control of cocaine use and continued use despite the negative consequences. Another of the central dimensions of this disorder is the craving (irresistible or irrepressible need or desire to consume) which is caused by internal or external stimuli. Craving is the cause of frequent loss of controls and re-consumption.

The treatment of cocaine addictions is generally based on a dual model of pharmacological treatment often aimed at limiting craving and psychotherapeutic treatment in order to alter the emotions and memory associated with cocaine use; for example: relearning product management when it comes to the subject.

In this context, the use of a 3D tool, which allows a gradual and well-detested exposure without confrontation, seems an interesting prospect. Virtual reality therapies have historically been known for treating phobias (fears). In addictions, exposure therapies are done in imagination and rarely with consumer-inducing situations. Since 2000, several researchers have successfully used virtual reality applications in addictions, but there is little data on objective assessments of the effectiveness of cybertherapy in the treatment of cocaine addictions.

All of these elements converge to propose a protocol called "CORVI" to evaluate the effectiveness of virtual reality exposure therapy as the management of patients with cocaine use disorder versus management classic.

The project is based on 3 phases: 1/construction of films that can be used in cybertherapy that reproduce situations in which there are stimuli generating "craving" to cocaine. 2/ Treatment of 2 randomized patient groups with and without cybertherapy (n-20/group) 3/Relapse evaluations at 1.2 and 3 months post-treatment


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 31, 2021
Est. primary completion date September 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- suffering from a cocaine use disorder with craving criteria present according to the criteria of DSM 5

- wanting to stop cocaine use

- able to give informed consent to participate in research

- Covered by a Social Security plan.

Exclusion Criteria:

Patient with:

- psychiatric comorbidities (DSM 5) unstabilized

- dipsomaniac alcoholism

- an anteriority of one or more hypomanic or manic episodes

- unstabilized psychosis

- an unstabilized depression

- a severe suicidal risk

- a syndrome of dependence on products other than cocaine or tobacco

- unstabilized anxiety

- problems that hinder participation in 3D exposure, as a tendency to dissociation; phobias of the type of information (panic attacks and hypochondria...) severe dizziness...

- cognitive problems limiting or preventing the possibility of implementing coping or managing emotions or stimuli and disabilities to complete questionnaires

- a language barrier

- a serious intercurrent pathology

- the need for weekly individual follow-up Patient in a protected population such as pregnant women, lactating women, patients under guardianship, guardianship, deprived of freedoms, or in safeguarding justice

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)
use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
Treatment as usual
Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)

Locations

Country Name City State
France CHU Clermont Ferrand Clermont-Ferrand Auvergne

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand Fondation de l'Avenir, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of relapser patients at 3 months post-intervention recovery in consumption of cocaine at M3 after intervention day 90 after intervention
Secondary Craving score evaluation of craving score (/10) compared to inclusion score day 30 after intervention
Secondary Craving score evaluation of craving score (/10) compared to inclusion score day 90 after intervention
Secondary Score on the personal efficiency sentiment scale Evaluation of the score on the personal efficiency sentiment scale day 30 after intervention
Secondary Score on the personal efficiency sentiment scale Evaluation of the score on the personal efficiency sentiment scale day 90 after intervention
Secondary Consumption of quantity of cocaine Evaluation of quantity of cocaine consumed day 30 after intervention
Secondary Consumption of quantity of cocaine Evaluation of quantity of cocaine consumed day 60 after intervention
Secondary Consumption of quantity of cocaine Evaluation of quantity of cocaine consumed day 90 after intervention
Secondary Frequency of consumption of cocaine Evaluation of the frequency of cocaine consumption day 30 after intervention
Secondary Frequency of consumption of cocaine Evaluation of the frequency of cocaine consumption day 60 after intervention
Secondary Frequency of consumption of cocaine Evaluation of the frequency of cocaine consumption day 90 after intervention
Secondary Way of consumption of cocaine Evaluation of the way of cocaine consumption day 30 after intervention
Secondary Way of consumption of cocaine Evaluation of the way of cocaine consumption day 60 after intervention
Secondary Way of consumption of cocaine Evaluation of the way of cocaine consumption day 90 after intervention
Secondary amount of cocaine consumed during relapse Evaluation of cocaine amount consumed during relapse day 30 after intervention
Secondary amount of cocaine consumed during relapse Evaluation of cocaine amount consumed during relapse day 90 after intervention
Secondary Frequence of cocaine consumed during relapse Evaluation of cocaine frequence consumption during relapse day 30 after intervention
Secondary Frequence of cocaine consumed during relapse Evaluation of cocaine frequence consumption during relapse day 90 after intervention
Secondary Percentage of relapser patients recovery in relapser patients at M1 after intervention day 30 after intervention
Secondary Duration of abstinence recovery of abstinence duration day 30 after intervention
Secondary Duration of abstinence recovery of abstinence duration day 60 after intervention
Secondary Duration of abstinence recovery of abstinence duration day 90 after intervention
See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000281 - Pharmacotherapy for Schizophrenic Drug Users - 6 Phase 2
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1